Initiation and completion rates for latent tuberculosis infection treatment: A systematic review

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Sandgren, Andreas ^c   Vonk Noordegraaf Schouten, Marije ^a   van Kessel, Femke ^a   Stuurman, Anke ^a   Oordt Speets, Anouk ^a   van der Werf, Marieke J ^b  

^a Pallas Health Research and Consultancy BV   (Netherlands)

^b NONE   (Sweden)

^c NONE

Author keywords

Latent tuberculosis; Risk groups; Treatment completion; Treatment initiation; Tuberculosis

Indexed keywords

HEALTH CARE PERSONNEL; HOMELESS PERSON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; MEDICATION COMPLIANCE; META ANALYSIS; MICROBIOLOGY; MIGRANT; STATISTICS AND NUMERICAL DATA;

EMIGRANTS AND IMMIGRANTS; HEALTH PERSONNEL; HIV INFECTIONS; HOMELESS PERSONS; HUMANS; LATENT TUBERCULOSIS; MEDICATION ADHERENCE;

EID: 84971255060     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1550-y     Document Type: Article

References (125)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Stockholm: ECDC; 2015.
2. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41:140-56.
3. Barry 3rd CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845-55.
4. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185:15-22.
5. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185:401-4.
6. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282:677-86.
7. National Institute for Health and Care Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE clinical guideline. Manchester: NICE; 2011. p. 67.
8. Canadian Tuberculosis Standards, 7th Edition. In: Menzies D, editor. Canadian Tuberculosis Standards. 7th ed. Ottawa: Canadian Thoracic Society, The Canadian Lung Association, Public Health Agency of Canada; 2014.
9. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1-54.
10. Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419-28.
11. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12:1235-54.
12. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14:551-9.
13. Anger HA, Proops D, Harris TG, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis. 2012;54:1287-95.
14. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14:e292-7.
15. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166:1863-70.
16. Nuzzo JB, Golub JE, Chaulk P, Shah M. Analysis of Latent Tuberculosis Infection Treatment Adherence Among Refugees and Other Patient Groups Referred to the Baltimore City Health Department TB Clinic, February 2009-March 2011. J Immigr Minor Health. 2015;17(1):56-65.
17. Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis. 2008;12:160-7.
18. Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect. 2013;67:424-32.
19. Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest. 2002;122:1609-14.
20. World Health Organization. Guidelines on the management of latent tuberculosis infection. 2015. p. 38.
21. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
22. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.
23. Lee SH, Yim JJ, Kim HJ, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect. 2012;140:1028-35.
24. Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent tuberculosis infection: screening and treatment in an urban setting. J Community Health. 2013;38:941-50.
25. Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12:468.
26. Machado Jr A, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis. 2009;13:719-25.
27. Centers for Disease Control and Prevention (CDC). Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection-Chickasaw County, Mississippi, June 1999-March 2002. MMWR Morb Mortal Wkly Rep. 2003;52:222-4.
28. Rutherford ME, Ruslami R, Anselmo M, et al. Management of children exposed to mycobacterium tuberculosis: a public health evaluation in west java, indonesia. Bull World Health Organ. 2013;91:932-41.
29. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295-300.
30. Lashley M. A targeted testing program for tuberculosis control and prevention among Baltimore city's homeless population. Public Health Nurs. 2007;24:34-9.
31. Brassard P, Bruneau J, Schwartzman K, Senecal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis. 2004;8:988-93.
32. Scholten JN, Driver CR, Munsiff SS, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis. 2003;37:1686-92.
33. Snyder DC, Paz EA, Mohle-Boetani JC, Fallstad R, Black RL, Chin DP. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999;160:178-85.
34. Bark CM, Morrison CS, Salata RA, et al. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda. Int J Tuberc Lung Dis. 2010;14:1647-9.
35. Oni T, Tsekela R, Kwaza B, et al. A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town. PLoS One. 2012;7:e52489.
36. Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest. 2002;122:1292-8.
37. Nolan CM, Roll L, Goldberg SV, Elarth AM. Directly observed isoniazid preventive therapy for released jail inmates. Am J Respir Crit Care Med. 1997;155:583-6.
38. Minodier P, Lamarre V, Carle ME, Blais D, Ovetchkine P, Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health. 2010;3:67-75.
39. Trauer JM, Krause VL. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust. 2011;194:579-82.
40. Young J, Edick T, Klee D, O'Connor ME. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J. 2012;31:e147-51.
41. Bastos ML, Menzies D, Belo MT, et al. Changes in QuantiFERON(R)-TB Gold In-Tube results during treatment for tuberculous infection. Int J Tuberc Lung Dis. 2013;17:909-16.
42. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640-7.
43. Jimenez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiro J, Altet-Gomez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17:326-32.
44. Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis. 1999;3:1043-6.
45. Matteelli A, Casalini C, Raviglione MC, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med. 2000;162:1653-5.
46. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445-9.
47. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689-97.
48. Rivero A, Lopez-Cortes L, Castillo R, et al. Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients. Enferm Infecc Microbiol Clin. 2007;25:305-10.
49. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922-6.
50. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715-22.
51. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66.
52. Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9:276-81.
53. Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest. 2001;119:833-7.
54. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-6.
55. Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis. 2005;9:270-5.
56. Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. J Urban Health. 1999;76:461-7.
57. Morisky DE, Ebin VJ, Malotte CK, Coly A, Kominski G. Assessment of tuberculosis treatment completion in an ethnically diverse population using two data sources. Implications for treatment interventions. Eval Health Prof. 2003;26:43-58.
58. Sadaphal P, Astemborski J, Graham NM, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687-91.
59. Sarivalasis A, Bodenmann P, Langenskiold E, Lutchmaya-Flick C, Daher O, Zellweger JP. High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton. Swiss Med Wkly. 2013;143:w13860.
60. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003;167:824-7.
61. Valls V, Ena J. Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy. Clin Rheumatol. 2014;34:29.
62. White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002;162:1044-50.
63. White MC, Tulsky JP, Menendez E, Goldenson J, Kawamura LM. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med. 2005;29:295-301.
64. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443-7.
65. Clerk N, Sisson K, Antunes G. Latent tuberculosis: concordance and duration of treatment regimens. Br J Nurs. 2011;20:824-7.
66. Duarte R, Carvalho A, Correia A. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection. Public Health. 2012;126:760-2.
67. Smith BM, Schwartzman K, Bartlett G, Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ. 2011;183:E173-9.
68. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med. 2006;3:e494.
69. O'Grady J, Maeurer M, Atun R, et al. Tuberculosis in prisons: anatomy of global neglect. Eur Respir J. 2011;38:752-4.
70. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med. 2000;162:460-4.
71. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-50.
72. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-55.
73. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592-5.
74. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013:828939.
75. Centers for Disease Control and Prevention (CDC). Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997. MMWR Morb Mortal Wkly Rep. 2000;49:685-7.
76. Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis. 2012;16:871-9.
77. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735-9.
78. Horsburgh Jr CR, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137:401-9.
79. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130:1712-7.
80. Lopez G, Wood M, Ayesta FJ. 10 years of innovation in the treatment of latent tuberculosis infection: a comparison between standard and short course therapies in directly observed therapy. Rev Esp Sanid Penit. 2011;13:3-14.
81. Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141:w13240.
82. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007;30:728-35.
83. Young H, Wessolossky M, Ellis J, Kaminski M, Daly JS. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Clin Infect Dis. 2009;49:424-7.
84. Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49:1883-9.
85. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545.
86. Eurostat Press Office. Immigration in the EU27 in 2006 In: newsrelease E, ed. 2008.
87. Comparing Migrant Stock: The Foreign Born in Australia, Canada, and the United States by Region of Origin. 2014. Accessed 15 Dec 2014.
88. Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist. 2010;3:63-72.
89. Cruz AT, Starke JR. Increasing adherence for latent tuberculosis infection therapy with health department-administered therapy. Pediatr Infect Dis J. 2012;31:193-5.
90. Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged > or =35 years. Clin Infect Dis. 2000;31:826-9.
91. Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 2008;133:862-8.
92. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh Jr CR. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007;54:262-6.
93. Cain KP, Garman KN, Laserson KF, et al. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med. 2012;186:273-9.
94. Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J. Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis. 2004;39:667-72.
95. Shah M, DiPietro D, Greenbaum A, et al. Programmatic impact of QuantiFERON-TB Gold In-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic. PLoS One. 2012;7:e36551.
96. Langenskiold E, Herrmann FR, Luong BL, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138:78-84.
97. Chee CB, Teleman MD, Boudville IC, Do SE, Wang YT. Treatment of latent TB infection for close contacts as a complementary TB control strategy in Singapore. Int J Tuberc Lung Dis. 2004;8:226-31.
98. Grinsdale JA, Ho CS, Banouvong H, Kawamura LM. Programmatic impact of using QuantiFERON(R)-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis. 2011;15:1614-20.
99. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033-8.
100. Balkhy HH, Miller TL, Ali S, et al. Compliance with postexposure screening and treatment of latent tuberculosis infection among healthcare workers in a tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol. 2014;35:176-81.
101. Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003;60:1856-61.
102. Xu Y, Schwartzman K. Referrals for positive tuberculin tests in new health care workers and students: a retrospective cohort study. BMC Public Health. 2010;10:28.
103. Golub JE, Astemborski J, Ahmed M, et al. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr. 2008;49:532-7.
104. Mugisha B, Bock N, Mermin J, et al. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis. 2006;10:761-7.
105. Lincoln T, Brannan GL, Lynch V, et al. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. Int J Tuberc Lung Dis. 2004;8:306-11.
106. Ailinger RL, Black P, Nguyen N, Lasus H. Predictors of Adherence to Latent Tuberculosis Infection Therapy in Latino Immigrants. J Community Health Nurs. 2007;24:191-8.
107. Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics. 2006;117:e148-56.
108. Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007;22:779-83.
109. Stucchi RS, Boin IF, Angerami RN, Zanaga L, Ataide EC, Udo EY. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Transplant Proc. 2012;44:2406-10.
110. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6:995-1000.
111. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis. 2005;41:1125-33.
112. Chang SH, Eitzman SR, Nahid P, Finelli ML. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents. J Infect Public Health. 2014;7:145-52.
113. Codecasa LR, Murgia N, Ferrarese M, et al. Isoniazid preventive treatment: predictors of adverse events and treatment completion. Int J Tuberc Lung Dis. 2013;17:903-8.
114. Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis. 2013;17:169-74.
115. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010;14:1104-11.
116. Kan B, Kalin M, Bruchfeld J. Completing treatment for latent tuberculosis: patient background matters. Int J Tuberc Lung Dis. 2013;17:597-602.
117. Vinnard C, Gopal A, Linkin DR, Maslow J. Isoniazid toxicity among an older veteran population: a retrospective cohort study. Tuberc Res Treat. 2013;2013:549473.
118. White MC, Gournis E, Kawamura M, Menendez E, Tulsky JP. Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco. Int J Tuberc Lung Dis. 2003;7:30-5.
119. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 2010;14:701-7.
120. Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest. 2005;127:1296-303.
121. Bandyopadhyay T, Murray H, Metersky ML. Cost-effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest. 2002;121:1771-5.
122. Priest DH, Vossel Jr LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis. 2004;39:1764-71.
123. Ailinger RL, Dear MR. Adherence to tuberculosis preventive therapy among Latino immigrants. Public Health Nurs. 1998;15:19-24.
124. Ailinger RL, Moore JB, Nguyen N, Lasus H. Adherence to latent tuberculosis infection therapy among latino immigrants. Public Health Nurs. 2006;23:307-13.
125. Sanchez-Garcia EM, Gamallo R, Blanco-Moure A, Viejo MA, Amador L, Anibarro L. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies. Infection. 2013;41:903-7.